Compare DigitalOcean Holdings Inc (DOCN) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Enveric Biosciences Inc — how do they compare? DigitalOcean Holdings Inc trades at $116.47 (market cap $13.18B), while Enveric Biosciences Inc trades at $1.32 (market cap $5.32M). The key difference: DigitalOcean Holdings Inc is far larger — about 2477.4× Enveric Biosciences Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| DOCN | ENVB | |
|---|---|---|
Market Cap | $13.18B | $5.32M |
Sector | Technology | Health |
52-Week High | $181.29 | $17.40 |
52-Week Low | $25.74 | $1.28 |
Enterprise Value | $13.74B | $408.82K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $123.32, down 5.49% today, with bearish technical signals but strong fundamental performance. The company reported record Q2 2026 results with revenue exceeding expectations and significant AI-driven growth. Analyst consensus remains bullish with a $174.80 price target, though technical indicators show selling pressure near-term.
The outlook remains positive given strong AI adoption and enterprise wins, with 63% analyst buy ratings supporting upside potential. Key risks include high valuation multiples and competitive cloud market pressures. The stock's current weakness presents a potential entry point for growth investors seeking AI infrastructure exposure.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
